
GRI Bio, a biotech company that specialises in treatment for inflammatory, fibrotic and autoimmune diseases, has announced that two global …

US clinical-stage biopharmaceutical company Kymera Therapeutics has shared newย data regarding its oncology programmes KT-333 and KT-413, highlighting their robust dose-dependent …

One of the worldโs bestselling drug may soon have competition in the US markets after the regulators backed a biosimilar …

Gilead Sciences is to pay $725million for the rights to filgotinib, a JAK1-selective inhibitor for rheumatoid arthritis and other inflammatory …
UK pharma giant GSK is partnering with the Medical Research Council, to study the biological mechanisms behind common inflammatory diseases. …